Search research articles
Contact Us
Filters
Showing results (11-20 of 43) with videos related to
Page
of 5
Sort By:
Journal of Drugs in Dermatology : JDD
|
June 2, 2021
Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex
Lawrence J Green, James Q Del Rosso, Emil A Tanghetti, et al.
Journal of Drugs in Dermatology : JDD
|
April 3, 2013
Evaluation of the efficacy, tolerability, and safety of an over-the-counter acne regimen containing benzoyl peroxide and salicylic acid in subjects with acne
Leon H Kircik, Jennifer Gwazdauskas, Victoria Butners, et al.
Journal of Drugs in Dermatology : JDD
|
April 14, 2021
A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream
Linda Stein Gold, Lawrence J Green, Sunil Dhawan, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|
February 15, 2021
Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program
Joel L Cohen, Lawrence J Green, Kenneth R Beer, et al.
Journal of Drugs in Dermatology : JDD
|
July 14, 2018
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
David M Pariser, Lawrence J Green, Linda Stein Gold, et al.
Aesthetic Surgery Journal
|
February 22, 2021
Improvements in Submental Contour up to 3 Years After ATX-101: Efficacy and Safety Follow-Up of the Phase 3 REFINE Trials
Shannon Humphrey, Joel L Cohen, Ashish C Bhatia, et al.
The Journal of Clinical and Aesthetic Dermatology
|
May 31, 2021
Tazarotene 0.045% Lotion for Moderate-to-Severe Acne in Male and Female Participants: A Phase II <i>Post-hoc</i> Analysis
Hilary E Baldwin, Lawrence J Green, Leon Kircik, et al.
Journal of Drugs in Dermatology : JDD
|
June 29, 2019
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris
Emil A. Tanghetti, Leon H. Kircik, Lawrence J. Green, et al.
Journal of Drugs in Dermatology : JDD
|
March 26, 2019
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
Andrew Blauvelt, Lawrence J. Green, Mark G. Lebwohl, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|
May 24, 2014
Who do you prefer? A study of public preferences for health care provider type in performing cutaneous surgery and cosmetic procedures in the United States
Haider K Bangash, Omar A Ibrahimi, Lawrence J Green, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 43) with videos related to
Sort By:
Page
of 5
Journal of Drugs in Dermatology : JDD
|
June 2, 2021
Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex
Lawrence J Green, James Q Del Rosso, Emil A Tanghetti, et al.
Journal of Drugs in Dermatology : JDD
|
April 3, 2013
Evaluation of the efficacy, tolerability, and safety of an over-the-counter acne regimen containing benzoyl peroxide and salicylic acid in subjects with acne
Leon H Kircik, Jennifer Gwazdauskas, Victoria Butners, et al.
Journal of Drugs in Dermatology : JDD
|
April 14, 2021
A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream
Linda Stein Gold, Lawrence J Green, Sunil Dhawan, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|
February 15, 2021
Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program
Joel L Cohen, Lawrence J Green, Kenneth R Beer, et al.
Journal of Drugs in Dermatology : JDD
|
July 14, 2018
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
David M Pariser, Lawrence J Green, Linda Stein Gold, et al.
Aesthetic Surgery Journal
|
February 22, 2021
Improvements in Submental Contour up to 3 Years After ATX-101: Efficacy and Safety Follow-Up of the Phase 3 REFINE Trials
Shannon Humphrey, Joel L Cohen, Ashish C Bhatia, et al.
The Journal of Clinical and Aesthetic Dermatology
|
May 31, 2021
Tazarotene 0.045% Lotion for Moderate-to-Severe Acne in Male and Female Participants: A Phase II <i>Post-hoc</i> Analysis
Hilary E Baldwin, Lawrence J Green, Leon Kircik, et al.
Journal of Drugs in Dermatology : JDD
|
June 29, 2019
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris
Emil A. Tanghetti, Leon H. Kircik, Lawrence J. Green, et al.
Journal of Drugs in Dermatology : JDD
|
March 26, 2019
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
Andrew Blauvelt, Lawrence J. Green, Mark G. Lebwohl, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|
May 24, 2014
Who do you prefer? A study of public preferences for health care provider type in performing cutaneous surgery and cosmetic procedures in the United States
Haider K Bangash, Omar A Ibrahimi, Lawrence J Green, et al.
Page
of 5